Insilico Medicine’s AI-driven drug Rentosertib receives official generic name

FHS
March 7, 2025
1:06 pm

Insilico Medicine(“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF) – Rentosertib (formerly known as ISM001-055) – has been granted an official generic name by the United States Adopted Names (USAN) Council.

How Well Do You Know 2024’s Top Stories?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

December 29, 2024

Scientists find way to restore brain’s self-cleaning function

Alzheimer’s, Parkinson’s, and other neurological disorders can be seen as “dirty brain” diseases, where the brain struggles to clear out harmful waste. Aging is a

August 16, 2024

Novartis CEO: Trying to crack obesity market with another first-gen agent is ‘not a prudent approach’

Novartis doesn’t want to play the me-too game in obesity. On Thursday, CEO Vas Narasimhan said that trying to compete in the multibillion-dollar obesity market

July 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.